Clinical Trials Logo

Uterine Fibroids clinical trials

View clinical trials related to Uterine Fibroids.

Filter by:

NCT ID: NCT02835391 Completed - Cancer Clinical Trials

PerClot Compared to Usual Care in Gynaecology Procedures

Start date: November 2015
Phase: N/A
Study type: Interventional

This study is a post market, multi-centre, randomised study evaluating PerClot compared to usual care. PerClot is a CE marked device and is currently used as a haemostat in gynaecological surgery throughout Europe. The purpose of this study is to collect additional post market data on its use in this indication.

NCT ID: NCT02819609 Completed - Uterine Fibroids Clinical Trials

Comparing Patient-Centered Outcomes After Treatment for Uterine Fibroids

Start date: November 2014
Phase: N/A
Study type: Observational

The purpose of this observational, retrospective database study of patients with uterine fibroids is to compare the durability of symptom relief after uterus-conserving treatments for symptomatic fibroids in terms of incidence of, and time to, new or recurrent symptoms and subsequent procedures and evaluate the effect stakeholder participation had on the research process.

NCT ID: NCT02691494 Completed - Uterine Fibroids Clinical Trials

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Start date: February 3, 2016
Phase: Phase 3
Study type: Interventional

This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

NCT ID: NCT02655237 Completed - Uterine Fibroids Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Start date: March 5, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids.

NCT ID: NCT02655224 Completed - Uterine Fibroids Clinical Trials

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Start date: March 26, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.

NCT ID: NCT02654054 Completed - Uterine Fibroids Clinical Trials

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Start date: December 22, 2015
Phase: Phase 3
Study type: Interventional

This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

NCT ID: NCT02472184 Completed - Uterine Fibroids Clinical Trials

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

Start date: October 2015
Phase: N/A
Study type: Interventional

This study will look at the optimal order in which to perform concurrent office hysteroscopy and endometrial biopsy in female patients who present for evaluation of abnormal uterine bleeding at a fibroid and endometriosis treatment center.

NCT ID: NCT02470741 Completed - Uterine Fibroids Clinical Trials

Pilot of Letrozole for Uterine Myomas

PLUM
Start date: July 2015
Phase: Phase 4
Study type: Interventional

PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).

NCT ID: NCT02323646 Completed - Uterine Fibroids Clinical Trials

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Start date: February 12, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and efficacy of two vaginal doses of Proellex® administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine fibroids.

NCT ID: NCT02301897 Completed - Uterine Fibroids Clinical Trials

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Start date: March 16, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and efficacy of two oral doses of Proellex administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine fibroids.